Finch Therapeutics Group 

Finch Therapeutics Group, Inc. is a U.S.-based, clinical-stage biotechnology company dedicated to developing innovative, orally administered biological drugs that leverage the microbiome. Its leading investigational therapy, CP101, is an orally delivered microbiome capsule currently in Phase 3 clinical trials. This candidate aims to treat patients suffering from recurrent Clostridioides difficile infection, as well as chronic hepatitis B virus. The company's pipeline also features FIN-211, an oral enriched consortia product candidate being developed for the treatment of autism spectrum disorder. Additionally, Finch is advancing TAK-524 and FIN-525, which are targeted oral consortia product candidates for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Finch Therapeutics maintains strategic collaboration and licensing agreements with partners such as Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota. Founded in 2014, Finch Therapeutics Group, Inc. operates from its headquarters in Somerville, Massachusetts.